AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

TY - JOUR

T1 - AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

AU - American Gastroenterological Association Institute Clinical Guidelines Committee

AU - Feuerstein, Joseph D.

AU - Ho, Edith Y.

AU - Shmidt, Eugenia

AU - Singh, Harminder

AU - Falck-Ytter, Yngve

AU - Sultan, Shanaz

AU - Terdiman, Jonathan P.

AU - Sultan, Shahnaz

AU - Cohen, Benjamin L.

AU - Chachu, Karen

AU - Day, Lukejohn

AU - Davitkov, Perica

AU - Lebwohl, Benjamin

AU - Levin, Theodore R.

AU - Patel, Amit

AU - Peery, Anne F.

AU - Shah, Raj

AU - Singh, Siddharth

AU - Spechler, Stuart J.

AU - Staller, Kyle

AU - Thrift, Aaron P.

AU - Weiss, Jennifer M.

N1 - Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda . Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada . Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report. Funding Information: Conflicts of interest These authors disclose the following: Eugenia Shmidt received research support from Celgene and Takeda. Harminder Singh served on the advisory board of Takeda Canada, Pendopharm, Ferring Merck Canada, and Guardant Health Inc., and also received educational funding from Ferring and research funding from Merck Canada. Harminder Singh also served an advisory role to Guardant Health. Jonathan P. Terdiman received research support from Abbvie. The remaining authors disclose no conflicts. All members were required to complete the disclosure statement. These statements are maintained at the American Gastroenterological Association headquarters in Bethesda, Maryland, and pertinent disclosures are published with this report.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85106495756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106495756&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2021.04.022

DO - 10.1053/j.gastro.2021.04.022

M3 - Article

C2 - 34051983

AN - SCOPUS:85106495756

SN - 0016-5085

VL - 160

SP - 2496

EP - 2508

JO - Gastroenterology

JF - Gastroenterology

IS - 7

ER -